Farname Inc. in collaboration with Iranian Society of Gynecology Oncology

Document Type : Original Research Article

Authors

Department of Obstetrics & Gynecology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

In gynecological cancers, sentinel lymph node (SLN) mapping has been proposed as an alternative to complete lymph node dissection. The goal of this study was to determine sentinel lymph node mapping's sensitivity, specificity, NPV, and PPV versus gold standard surgery (complete lymph node dissection) in patients with metastatic illness. A total of 26 patients were prospectively enrolled from spring 2021 to winter 2022. Sentinel lymph node mapping with complete pelvic lymph node dissection was done in all of them, and para-aortic lymphadenectomy was detected in 11 (43.33%) patients. At least one sentinel lymph node was successfully mapped in 22 (84.6%) patients. Three patients (11.5%) had positive lymph nodes, with an 85.7% sensitivity (95 percent CI) to detect node positive illness, a specificity of 74.93%, an NPV of 99.6 (99.5 CI), and a PPV of 5.9% calculated. There were no serious adverse effects due to blue dye. The accuracy rate of sentinel lymph node mapping by methylene blue was 75.1%.

Highlights

 The goal of this study was to determine sentinel lymph node mapping's sensitivity, specificity, NPV, and PPV versus gold standard surgery (complete lymph node dissection) in patients with metastatic illness.

Keywords

Main Subjects

1. Staley A, Sullivan SA, Rossi EC. Sentinel lymph node technique in endometrial cancer. Obstet Gynecol Surv. 2017;72(5):289-95. [DOI:10.1097/OGX.0000000000000425] [PMID]
2. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group study. Cancer. 1987;60(S8):2035-41.  [DOI:10.1002/1097-0142(19901015)60:8+<2035::AID-CNCR2820601515>3.0.CO;2-8] [PMID]
3. Burke WM, Orr J, Leitao M, Salom E, Gehrig P, Olawaiye AB, et al. Endometrial cancer: a review and current management strategies: part II. Gynecol Oncol. 2014;134(2):393-402. [DOI:10.1016/j.ygyno.2014.05.018] [DOI:10.1016/j.ygyno.2014.06.003] [PMID]
4. Abu-Rustum NR, Alektiar K, Iasonos A, Lev G, Sonoda Y, Aghajanian C, et al. The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center. Gynecol Oncol. 2006;103(2):714-8. [DOI:10.1016/j.ygyno.2006.03.055] [PMID]
5. Cardosi RJ, Cox CS, Hoffman MS. Postoperative neuropathies after major pelvic surgery. Obstet Gynecol. 2002;100(2):240-4. [DOI:10.1097/00006250-200208000-00007] [DOI:10.1016/S0029-7844(02)02052-5] [PMID]
6. AJ BS, Fader A, Tanner E. Sentinel lymph node assessment in endometrial cancer: a systematic review and meta-analysis. Am J Obstet Gynecol. 2016;216(5):459-76. e10. [DOI:10.1016/j.ajog.2016.11.1033] [PMID]
7. Allameh T, Hashemi V, Mohammadizadeh F, Behnamfar F. Sentinel lymph node mapping in early stage of endometrial and cervical cancers. J Res Med Sci. 2015;20(2):169-73.
8. Bats A-S, Buénerd A, Querleu D, Leblanc E, Daraï E, Morice P, et al. Diagnostic value of intraoperative examination of sentinel lymph node in early cervical cancer: a prospective, multicenter study. Gynecol Oncol. 2011;123(2):230-5. [DOI:10.1016/j.ygyno.2011.08.010] [PMID]
9. Raimond E, Ballester M, Hudry D, Bendifallah S, Daraï E, Graesslin O, et al. Impact of sentinel lymph node biopsy on the therapeutic management of early-stage endometrial cancer: Results of a retrospective multicenter study. Gynecol Oncol. 2014;133(3):506-11. [DOI:10.1016/j.ygyno.2014.03.019] [PMID]
10. Touhami O, Trinh XB, Gregoire J, Sebastianelli A, Renaud MC, Grondin K, et al. Predictors of non-sentinel lymph node (non-SLN) metastasis in patients with sentinel lymph node (SLN) metastasis in endometrial cancer. Gynecol Oncol. 2015;138(1):41-5. [DOI:10.1016/j.ygyno.2015.04.008] [PMID]
11. Vidal F, Leguevaque P, Motton S, Delotte J, Ferron G, Querleu D, et al. Evaluation of the sentinel lymph node algorithm with blue dye labeling for early-stage endometrial cancer in a multicentric setting. Int J Gynecol Cancer. 2013;23(7):1237-43. [DOI:10.1097/IGC.0b013e31829b1b98] [PMID]
12. Sawicki S, Lass P, Wydra D. Sentinel Lymph Node Biopsy in Endometrial Cancer--Comparison of 2 Detection Methods. Int J Gynecol Cancer. 2015;25(6):1044-50. [DOI:10.1097/IGC.0000000000000447] [PMID]
13. Basta A, Pityński K, Basta P, Hubalewska-Hoła A, Opławski M, Przeszlakowski D. Sentinel node in gynaecological oncology. Reports of Practical Oncology and Radiotherapy. 2005;10(2):24-7. [DOI:10.1016/S1507-1367(05)71114-7]
14. Buda A, Crivellaro C, Elisei F, Di Martino G, Guerra L, De Ponti E, et al. Impact of Indocyanine Green for Sentinel Lymph Node Mapping in Early Stage Endometrial and Cervical Cancer: Comparison with Conventional Radiotracer (99m)Tc and/or Blue Dye. Ann Surg Oncol. 2016;23(7):2183-91. [DOI:10.1245/s10434-015-5022-1] [PMID] [PMCID]
15. Tanner EJ, Sinno AK, Stone RL, Levinson KL, Long KC, Fader AN. Factors associated with successful bilateral sentinel lymph node mapping in endometrial cancer. Gynecol Oncol. 2015;138(3):542-7. [DOI:10.1016/j.ygyno.2015.06.024] [PMID]
16. Daraï E, Dubernard G, Bats A-S, Heitz D, Mathevet P, Marret H, et al. Sentinel node biopsy for the management of early stage endometrial cancer: long-term results of the SENTI-ENDO study. Gynecol oncol. 2015;136(1):54-9. [DOI:10.1016/j.ygyno.2014.09.011] [PMID]
17. Farghali MM, Allam IS, Abdelazim IA, El-Kady OS, Rashed AR, Gareer WY, et al. Accuracy of Sentinel Node in Detecting Lymph Node Metastasis in Primary Endometrial Carcinoma. Asian Pac J Cancer Prev APJCP. 2015;16(15):6691-6. [DOI:10.7314/APJCP.2015.16.15.6691] [PMID]
18. Lin H, Ding Z, Kota VG, Zhang X, Zhou J. Sentinel lymph node mapping in endometrial cancer: a systematic review and meta-analysis. Oncotarget. 2017;8(28):46601. [DOI:10.18632/oncotarget.16662] [PMID] [PMCID]
19. Kuru O, Topuz S, Sen S, Iyibozkurt C, Berkman S. Sentinel lymph node biopsy in endometrial cancer: description of the technique and preliminary results. J Turk Ger Gynecol Assoc. 2011;12(4):204-8. [DOI:10.5152/jtgga.2011.52] [PMID] [PMCID]
20. Kadkhodayan S, Shiravani Z, Hasanzadeh M, Sharifi N, Yousefi Z, Fattahi A, et al. Lymphatic mapping and sentinel node biopsy in endometrial cancer--a feasibility study using cervical injection of radiotracer and blue dye. Nucl Med Rev Cent East Eur. 2014;17(2):55-8. [DOI:10.5603/NMR.2014.0017] [PMID]
21. Gien LT, Kwon JS, Carey MS. Sentinel node mapping with isosulfan blue dye in endometrial cancer. J Obstet Gynaecol Can. 2005;27(12):1107-12. [DOI:10.1016/S1701-2163(16)30393-0] [PMID]
22. Eitan R, Sabah G, Krissi H, Raban O, Ben-Haroush A, Goldschmit C, et al. Robotic blue-dye sentinel lymph node detection for endometrial cancer - Factors predicting successful mapping. Eur J Surg Oncol. 2015;41(12):1659-63. [DOI:10.1016/j.ejso.2015.09.006] [PMID]
23. Koskas M, Chereau E, Ballester M, Dubernard G, Lécuru F, Heitz D, et al. Accuracy of a nomogram for prediction of lymph-node metastasis detected with conventional histopathology and ultrastaging in endometrial cancer. Bri J Cancer. 2013;108(6):1267-72. [DOI:10.1038/bjc.2013.95] [PMID] [PMCID]
24. Niikura H, Kaiho-Sakuma M, Tokunaga H, Toyoshima M, Utsunomiya H, Nagase S, et al. Tracer injection sites and combinations for sentinel lymph node detection in patients with endometrial cancer. Gynecol Oncol. 2013;131(2):299-303. [DOI:10.1016/j.ygyno.2013.08.018] [PMID]
25. Selman TJ, Mann CH, Zamora J, Khan KS. A systematic review of tests for lymph node status in primary endometrial cancer. BMC women's health. 2008;8:8. [DOI:10.1186/1472-6874-8-8] [PMID] [PMCID]
26. Ruscito I, Gasparri ML, Braicu EI, Bellati F, Raio L, Sehouli J, et al. Sentinel Node Mapping in Cervical and Endometrial Cancer: Indocyanine Green Versus Other Conventional Dyes-A Meta-Analysis. Ann Surg Oncol. 2016;23(11):3749-56. [DOI:10.1245/s10434-016-5236-x] [PMID]